Zeynoc, I agree with your points on the reporting and
Zeynoc, I agree with your points on the reporting and expressed such over the weekend only to have my post "deleted" IF DECN cites a topic or names companies that agreements are or will be signed up, that becomes PUBLIC information and as such it is REASONABLE to have continued QUARTERLY repirted informstion until such time the project is ceased. Anything else MAY be perceived by investors as ingenious or non-transparent. This would give DECN an opportunity to tout positives and show that negativesare learned from and moved away from in lieu of a bad trade.
A local clothing retailer used a tagline for years very successfully, "An educated customer is our BEST customer"......IMO DECN would be better searved with better communications in the form of Zeynoc's point of subsequent project staus albeit at least 4 times a year.
I hope dissent does not become the trigger for deletion on this DISCUSSION board and I due applaud the small improvement on civility although the veiled disparagement still seems to get through
1
Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Key Opportunity for Coinbase Investors Investors holding Coinbase Global, Inc. (NASDAQ: COIN) securities may have a significant opportunity to participate in a class action lawsuit alleging serious violations of securities regulations. This opportunity arises from actions that took place during the specified Class Period. Investors are encouraged to evaluate their...
Continue Reading
BridGene Biosciences Raises Significant Funding BridGene Biosciences, Inc., renowned for its innovative approach in developing small molecule drugs, recently announced the completion of a substantial $28 million Series B+ financing round. This funding round was spearheaded by Bayland Capital, alongside notable contributions from GTJA Investment Group, Proxima Ventures,...
Continue Reading
NMD Pharma's Innovative Phase 2 Study with NMD670 NMD Pharma A/S, an ambitious clinical-stage biotech company, is making strides in the fight against neuromuscular diseases. They have officially begun their Phase 2a clinical trial of NMD670, a novel treatment aimed at addressing the challenges faced by patients with Charcot-Marie-Tooth (CMT) disease types 1 and 2. This...
Continue Reading
Introduction to Becker Milk Company's Financial Landscape Becker Milk Company Limited is making headlines with its financial results for the first half of its fiscal year. The latest report showcases their performance, reflecting on revenues and net income trends. Financial Highlights Overview Total revenues for the first six months reveal a detail-oriented insight into...
Continue Reading
Exciting New Flavor Launch from Mini Melts and 7-Eleven In an exciting collaboration, Mini Melts USA, a leader in premium beaded ice cream, has partnered with 7-Eleven, Inc. to introduce a new flavor reminiscent of the classic Blue Raspberry Slurpee. This innovative flavor captures the essence of the much-loved frozen drink, providing fans with a delightful and nostalgic...
Continue Reading
